DUBLIN–(BUSINESS WIRE)–The “Short Bowel Syndrome – Market Insight, Epidemiology and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
This report deliver an in-depth understanding of the Short Bowel Syndrome (SBS), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Short Bowel Syndrome (SBS) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted SBS symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Short Bowel Syndrome (SBS) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Country Wise- Short Bowel Syndrome (SBS) Epidemiology
The epidemiology segment also provides the Short Bowel Syndrome (SBS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total 7MM prevalent cases of Short Bowel Syndrome (SBS) were 34,713 cases in 2020.
Short Bowel Syndrome (SBS) Drug Chapters
The drug chapter segment of the Short Bowel Syndrome (SBS) report encloses the detailed analysis of SBS marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Short Bowel Syndrome (SBS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Management of short bowel syndrome requires a multi-disciplinary approach that includes neonatologists, gastroenterologists, surgeons, nutritionists, pharmacists, nurses, and social workers. Guidelines have been set forth regarding the optimal SBS classification and management, but they must be taken in the context of the situation and cannot be used in every circumstance. Treatment includes Parenteral Nutrition and Enteral Nutrition and usually involves medications to help ease your signs and symptoms and increase the absorption rate.
Competitive Intelligence Analysis
The publisher performs a Competitive and Market Intelligence analysis of the Short Bowel Syndrome (SBS) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Short Bowel Syndrome (SBS), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
- Comprehensive insight has been provided into the Short Bowel Syndrome (SBS) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies Short Bowel Syndrome (SBS) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Short Bowel Syndrome (SBS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies by understanding trends shaping and driving the global Short Bowel Syndrome (SBS) market
Report Highlights
- In the coming years, Short Bowel Syndrome (SBS) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Short Bowel Syndrome (SBS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for SBS. The launch of emerging therapies will significantly impact the Short Bowel Syndrome (SBS) market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for SBS.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Companies Mentioned
- Takeda
- Zealand Pharma
- VectivBio AG
- 9 Meters Biopharma
For more information about this report visit https://www.researchandmarkets.com/r/gk3mdc
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900